Characteristic | OS-6 (%) | mOS (months) | p= |
---|---|---|---|
< 50 years at Re-RT | 73 ± 9 | 9.4 ± 1.4 | 0.015 |
≥ 50 years at Re-RT | 50 ± 8 | 5.8 ± 1.4 | |
Male | 60 ± 9 | 7.7 ± 0.8 | 0.669 |
Female | 59 ± 9 | 7.7 ± 1.7 | |
WHO IV | 55 ± 7 | 7.4 ± 1.4 | 0.009 |
WHO III | 82 ± 12 | 11.2 ± 10.5 | |
Karnofsky performance score < 70 | 34 ± 14 | 5.0 ± 1.0 | 0.002 |
Karnofsky performance score ≥ 70 | 66 ± 7 | 8.1 ± 0.8 | |
Time from RT to Re-RT ≤ 12 months | 52 ± 11 | 6.9 ± 2.5 | 0.140 |
Time from RT to Re-RT > 12 months | 63 ± 8 | 8.1 ± 1.1 | |
No concurrent chemotherapy1 | 52 ± 10 | 6.6 ± 2.9 | 0.001 (3 vs 2) |
Carboplatin/etoposide2 | 54 ± 10 | 6.7 ± 1.3 | 0.006 (3 vs 1) |
Temozolomide3 | 92 ± 8 | 27.0 ± 17.6 | 0.455 (2 vs 1) |
Complete resection before Re-RT | 100 | 17.5 ± 3.4 | 0.034 |
Incomplete/no resection before Re-RT | 55 ± 7 | 7.4 ± 1.3 |